Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELI LILLY & CoLLY · Entity 2794 | EVP & CFO | February 16, 2026 | February 18, 2026 |
| Elanco Animal Health IncELAN · Entity 3457 | Acting Chief Financial Officer | September 19, 2018 | September 19, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELI LILLY & Co
Report date February 16, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,258.473 |
Ending reported balance
After 2026-02-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-16 · Exercise / conversion · Acquired 368 · Balance 16,418.206 Row 2 · 2026-02-16 · Tax withholding · Disposed 159.733 · Balance 16,258.473 |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2026-02-16 | Direct | 0 |
Reported balance
After 2026-02-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-16 · Exercise / conversion · Disposed 368 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.
Elanco Animal Health Inc
Report date September 19, 2018 · Filed September 19, 2018
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2026 Filed Feb 18, 2026 21:21 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 368 | $0.00 | $0.00 |
DisclosureSEC source: 0001752447-26-000004 · wk-form4_1771449713.xml · derivative · entry 3 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 368 shares Expires 2026-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:21 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 159.733 | $1,040.00 | $166,122.32 |
DisclosureSEC source: 0001752447-26-000004 · wk-form4_1771449713.xml · nonDerivative · entry 2 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,258.473 Read SEC document |
| February 16, 2026 Filed Feb 18, 2026 21:21 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 368 | $0.00 | $0.00 |
DisclosureSEC source: 0001752447-26-000004 · wk-form4_1771449713.xml · nonDerivative · entry 1 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,418.206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:20 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 1,365.47 | $1,044.67 | $1,426,465.54 |
DisclosureSEC source: 0001752447-26-000002 · wk-form4_1770844810.xml · nonDerivative · entry 1 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,050.206 Read SEC document |
| August 15, 2025 Filed Aug 15, 2025 20:13 UTC | ELI LILLY & Co LLY · Entity 2794 | PurchaseCommon Stock | 715 | $691.79 | $494,626.99 |
DisclosureSEC source: 0000059478-25-000222 · wk-form4_1755288778.xml · nonDerivative · entry 1 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,684.736 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $691.67 to $691.90, inclusive. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:26 UTC | ELI LILLY & Co LLY · Entity 2794 | GrantCommon Stock | 2,895.932 | $868.88 | $2,516,217.40 |
DisclosureSEC source: 0000059478-25-000053 · wk-form4_1739395561.xml · nonDerivative · entry 1 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,969.736 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionRestricted Stock Unit · Derivative | 1,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000253 · wk-form4_1730841326.xml · derivative · entry 3 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,074 shares Expires 2024-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | Tax withholdingCommon Stock | 467.196 | $818.93 | $382,600.82 |
DisclosureSEC source: 0000059478-24-000253 · wk-form4_1730841326.xml · nonDerivative · entry 2 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,073.804 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:15 UTC | ELI LILLY & Co LLY · Entity 2794 | Exercise / conversionCommon Stock | 1,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-24-000253 · wk-form4_1730841326.xml · nonDerivative · entry 1 Montarce Lucas · CIK 0001752447 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,541 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.